Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting

Posted on by

WALTHAM, Mass., May 18, 2023 /PRNewswire/ — Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for both rare and prevalent devastating diseases, today announced the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.